Neuren Pharmaceuticals

Company profile

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in preclinical trial stage for the treatment of Prader-Willi syndrome, Hypoxic Ischemic Encephalopathy, and SYNGAP1. The company was incorporated in 2001 and is based in Hawthorn East, Australia.

Company facts

Sector

Healthcare

Industry

Biotechnology

Country

Australia

Headquarters

117 Camberwell Road, 3123, Hawthorn East

Listing

NEU · ASX

Indices

S&P/ASX 200

Currency

AUD

ISIN

NZNEUE0001S8

Website

neurenpharma.com